Example: marketing
PARACETAMOL-AFT - Medsafe
Paracetamol is metabolised mainly in the liver following two major hepatic pathways: glucuronic acid conjugation and sulphuric acid conjugation.
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Heparin sodium salt - HiMedia Labs
himedialabs.comHeparin sodium salt Cell Culture Tested Product Code: TC138 Please refer disclaimer overleaf Product Description : CAS No.: 9041-08-1 Heparin is a …
METALAXYL-M (212) - Food and Agriculture …
www.fao.org405 METALAXYL-M (212) First draft prepared by Denis Hamilton, Department of Primary Industries and Fisheries, Brisbane, Australia EXPLANATION
5.19 PROTHIOCONAZOLE (232) TOXICOLOGY
www.fao.orgProthioconazole 265 5.19 PROTHIOCONAZOLE (232) TOXICOLOGY Prothioconazole is the ISO approved common name for the substance for which the IUPAC
PRODUCT INFORMATION Deptran - Medicines
www.medicines.org.auPRODUCT INFORMATION Deptran Doxepin (as hydrochloride) NAME OF THE MEDICINE Active ingredient : Doxepin hydrochloride Chemical name : 11-[3-dimethylaminopropylidene]-6H-dibenz[b,e]oxepin hydrochloride
Mobilis - Medicines
www.medicines.org.auMobilis – Product Information 2 Inhibition of prostanoid synthesis including prostaglandins, through a reversible inhibition of the cyclooxygenase enzyme.
Cats, Essential Oils & Aromatherapy? Essential Oil
www.thelavendercat.comTheLavenderCat - Aromatherapy & Cats - The Lavender Cat - Essential Oil Safety For Cats Home Cats & Aromatherapy Dr. Khan DVM, DABVT, ASPCA Toxicology
Injectable Fillers: Review of Material and Properties
www.tulipmedical.comInjectable Fillers: Review of Material and Properties Natalie Huang Attenello, MD2 Corey S. Maas, MD, FACS1,2 1Department of Facial Plastic and …